Intuitive Machines expects to begin manufacturing and flight integration on its orbital transfer vehicle as soon as 2026. Photo courtesy Intuitive Machines.

Houston-based Intuitive Machines, which rang the NASDAQ opening bell July 31, has secured a $9.8 million Phase Two government contract for its orbital transfer vehicle.

The contract will push the project through its Critical Design Review phase, which is the final engineering milestone before manufacturing can begin, according to a news release from the company.

Intuitive Machine's orbital transfer vehicle (OTV) is designed to transfer payloads between Earth's orbit and the Moon and is built around the company's Nova-C lander, which has been a part of two successful lunar missions.

“Our OTV is a direct evolution of our lunar surface delivery missions—positioning us to expand into the rapidly growing market for in-space logistics,” Steve Altemus, Intuitive Machines CEO, said in the release. “We’re leveraging our flight-proven technology to operate a mission-ready service that delivers customer payloads across orbits—from Earth to the Moon and beyond.”

The company says the fast, flexible vehicle could be used for orbital servicing, logistics and communications in medium earth orbit, low lunar orbit and a variety of other destinations.

Intuitive Machines expects to begin manufacturing and flight integration as soon as 2026, once the design review is completed.

The non-NASA contract is for an undisclosed government customer, which Intuitive Machines says reinforces its "strategic move to diversify its customer base and deliver orbital capabilities that span commercial, civil, and national security space operations."

The company has received millions from NASA for its lunar rover, lunar lander, science and technology payloads, and communications and navigation services over the years. It also recently landed up to $10 million to help develop an Earth re-entry vehicle and in-space biomanufacturing lab from Texas's Space Exploration and Research Fund.

Earlier this month, the City of Houston agreed to add three acres of commercial space for Intuitive Machines at the Houston Spaceport at Ellington Airport. Read more here.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

TMC launches new biotech partnership with Republic of Korea

international collaboration

Houston's Texas Medical Center has launched its new TMC Republic of Korea BioBridge.

The new partnership brings together the TMC with the Osong Medical Innovation Foundation, or KBIOHealth. The Biobridge aims to support the commercialization of Korean biotech and life science startups in the U.S., foster clinical research, and boost collaboration in the public, private and academic sectors.

Through the partnership, TMC will also develop a Global Innovators Launch Pad to foster U.S. market entry for international health care companies. Founders will be selected to participate in the 10-week program at the TMC Innovation Factory in Houston.

“Gene and cell therapies are driving biotech innovation, opening possibilities for treating diseases once thought untreatable," William McKeon, president and CEO of the Texas Medical Center, said in a news release. "Expanding biomanufacturing capacity is essential to delivering the next wave of these therapies, and partnerships with leading innovators will strengthen our efforts in Houston and internationally.”

McKeon officially signed the TMC Korea BioBridge Memorandum of Understanding with Myoung Su Lee, chairman of KBIOHealth, in South Korea in October.

"This collaboration marks a significant milestone for Korea’s biohealth ecosystem, creating a powerful bridge between Osong and Houston," Lee added in the release. "By combining KBIOHealth’s strength in research infrastructure and Korea’s biotech talent with TMC’s global network and accelerator platform, we aim to accelerate innovation and bring transformative solutions to patients worldwide.”

This is the seventh international strategic partnership for the TMC. It launched its first BioBridge with the Health Informatics Society of Australia in 2016. It launched its TMC Japan BioBridge, focused on advancing cancer treatments, last year. It also has BioBridge partnerships with the Netherlands, Ireland, Denmark and the United Kingdom.